Trial Profile
A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED COMPARISON OF THE EFFICACY, SAFETY, AND TOLERABILITY OF CELECOXIB 100-150 MG, INCLUDING INITIAL DOSES OF 50 AND 100 MG, AND PLACEBO IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH PAINFUL PHARYNGITIS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Feb 2009 Patient number amended from 268 to 269 as reported by ClinicalTrials.gov.
- 04 Jun 2007 Status changed from recruiting to in progress.
- 28 Feb 2007 New trial record.